Search clinical trials for: Akebia (AKB)

Total 56 results

Aerpio Therapeutics

Completed

Single Ascending Dose Study to Assess the Safety, Tolerability, PK and PD Effects in Male Volunteers

IBD

Canada
The University of Texas Health Science Center,...
United States Department of Defense; Akebia Therapeutics Inc.

Completed

Vadadustat for the Prevention and Treatment of Acute Respiratory Distress Syndrome (ARDS) in Hospitalized Patients With Coronavirus Disease 2019 (COVID-19)

Coronavirus Infection | Acute Respiratory Distress Syndrome

United States
Akebia Therapeutics

Completed

Dose-Finding Study of Vadadustat in Japanese Subjects With Anemia Secondary to Dialysis-Dependent Chronic Kidney Disease (DD-CKD)

Anemia | Dialysis Dependent Chronic Kidney Disease

Japan
Akebia Therapeutics

Suspended

Study to Evaluate the Safety and Efficacy of Oral Vadadustat in Pediatric Participants With Anemia of Chronic Kidney Disease Naive to Erythropoiesis-Stimulating Agents (CORRECTION)

Anemia of Chronic Kidney Disease

United States
Akebia Therapeutics

Completed

Study to Assess the Safety and Pharmacokinetics of AKB-6548 in Participants With Chronic Kidney Disease (CKD), Stages 3 and 4

Chronic Kidney Disease

United States
Akebia Therapeutics

Completed

A Single Dose Study of Oral Vadadustat in Subjects With Normal and Impaired Hepatic Function

Hepatic Impairment

United States
Akebia Therapeutics

Completed

A Study in Evaluating Bioequivalence of Test and Reference Vadadustat 450 MG and 150 MG Tablets and to Determine Food Effect on the 450 MG Tablet

Healthy

United States
Akebia Therapeutics

Suspended

Study to Evaluate the Safety and Efficacy of Oral Vadadustat in Pediatric Participants With Anemia of Chronic Kidney Disease (CONVERSION)

Anemia of Chronic Kidney Disease

United States
Aerpio Therapeutics

Completed

Open Label Study to Assess the Efficacy and Safety of AKB-9778 in Subjects With Macular Edema Due to RVO

Retinal Vein Occlusion

United States
Akebia Therapeutics

Completed

Dose-Finding Study of Vadadustat in Japanese Subjects With Anemia Secondary to Non-Dialysis Dependent Chronic Kidney Disease (NDD-CKD)

Anemia | Non-dialysis Dependent Chronic Kidney Disease

Japan
Mitsubishi Tanabe Pharma Corporation

Completed

Efficacy and Safety Study to Evaluate MT-6548 in Hemodialysis Subjects Not Receiving ESAs With Anemia Associated With Chronic Kidney Disease in Japan

Anemia; Hemodialysis Dependent Chronic Kidney Disease

Japan
Aerpio Therapeutics

Completed

Safety and Pilot Efficacy of AKB-9778 in Subjects With Diabetic Macular Edema

Diabetic Macular Edema (DME)

United States
Mitsubishi Tanabe Pharma Corporation

Completed

Efficacy and Safety Study to Evaluate MT-6548 in Peritoneal Dialysis Subjects With Anemia Associated With Chronic Kidney Disease in Japan

Anemia; Peritoneal Dialysis Dependent Chronic Kidney Disease

Japan
Aerpio Therapeutics

Completed

Study to Assess the Absorption, Metabolism, Excretion and Pharmacokinetics of [14C]-AKB-9778

Healthy
Akebia Therapeutics

Completed

Safety and Efficacy Study for AKB-6548 in Participants With Chronic Kidney Disease and Anemia

Anemia | Kidney Disease

United States
Akebia Therapeutics

Completed

42-Day Repeat Oral Dose Study of AKB-6548 in Participants With Chronic Kidney Disease and Anemia

Anemia | Kidney Disease

United States
Akebia Therapeutics

Completed

Relative Bioavailability of Two Formulations of AKB-6548 and the Food Effect of a New Tablet in Healthy Adult Subjects

Healthy

United States
Akebia Therapeutics

Completed

Study of Vadadustat in Hemodialysis Participants With Anemia Switching From Epoetin Alfa (FO2RWARD-2)

Anemia | Dialysis-dependent Chronic Kidney Disease

United States
Akebia Therapeutics

Completed

Effect of AKB-6548 on the Pharmacokinetics of Celecoxib

Healthy Volunteers
Akebia Therapeutics

Completed

Effects of Ferrous Sulfate on the Pharmacokinetics of AKB-6548

Healthy Volunteers

United States
Akebia Therapeutics

Completed

20-Week Repeat Oral Dose Study of AKB-6548 in Participants With Chronic Kidney Disease and Anemia

Anemia | Chronic Kidney Disease

United States
Aerpio Therapeutics

Completed

Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AKB-9778 Ophthalmic Solution

Primary Open Angle Glaucoma | Ocular Hypertension

United States
Arizona State University
Christopher Wharton; Eric Bartholomae; April Incollingo; Maricarmen Vizcaino

Completed

Effect of Supplementary Dietary Protein (21g Per Day) on Lean Mass and Strength in Sedentary, Adult Vegetarians (MungBean)

Muscle Weakness

United States
Akebia Therapeutics

Completed

Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment of Anemia in Participants With Dialysis-dependent Chronic Kidney Disease (DD-CKD)

Anemia | Dialysis-Dependent Chronic Kidney Disease

United States, Italy, Canada, Korea, Republic of, United Kingdom, Australia, Germany, Israel, France, Portugal, Bulgaria, Russian Federation, Ukraine, Poland, Brazil, Argentina, Mexico, Serbia
Akebia Therapeutics

Completed

Effect of AKB-6548 on Cardiac Repolarization Intervals in Healthy Volunteers

Healthy Volunteers

United States
Akebia Therapeutics

Completed

Efficacy and Safety Study to Evaluate Vadadustat for the Maintenance Treatment of Anemia in Participants With Non-dialysis-dependent Chronic Kidney Disease (NDD-CKD)

Anemia | Non-Dialysis-Dependent Chronic Kidney Disease

United States, Italy, Spain, Czechia, Korea, Republic of, Malaysia, Australia, New Zealand, United Kingdom, Germany, Turkey, Ukraine, France, Hungary, Austria, Israel, Bulgaria, Russian Federation, Romania, Slovakia, South Africa, Canad... and more
Akebia Therapeutics

Completed

Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Vadadustat in Hemodialysis Subjects With Anemia Associated With Chronic Kidney Disease

Anemia Associated With Chronic Kidney Disease

United States
EyePoint Pharmaceuticals, Inc.

Completed

The TIME-2b Study: A Study of AKB-9778 (Razuprotafib), a Novel Tie 2 Activator, in Patients With Non-Proliferative Diabetic Retinopathy (NPDR) (TIME-2b)

Nonproliferative Diabetic Retinopathy

United States
Mitsubishi Tanabe Pharma Corporation

Completed

Efficacy and Safety Study to Evaluate MT-6548 in Non-dialysis Subjects With Anemia Associated With Chronic Kidney Disease in Japan

Anemia; Non-dialysis Dependent Chronic Kidney Disease

Japan
Akebia Therapeutics

Terminated

Study to Evaluate Vadadustat for Anemia in Subjects With Dialysis-Dependent Chronic Kidney Disease (DD-CKD) Who Are Hyporesponsive to Erythropoiesis Stimulating Agents

Anemia | Dialysis-Dependent Chronic Kidney Disease

United States
Akebia Therapeutics

Withdrawn

Study to Evaluate Three Times Per Week (TIW) Oral Dosing of Vadadustat for Anemia in Subjects With Dialysis-Dependent Chronic Kidney Disease (DD-CKD) (TRILOGY)

Anemia | Dialysis-Dependent Chronic Kidney Disease

United States
Akebia Therapeutics

Completed

Study to Evaluate Vadadustat for the Correction of Anemia in Participants With Non-dialysis-dependent Chronic Kidney Disease

Anemia | Non-Dialysis-Dependent Chronic Kidney Disease

United States, Italy, Korea, Republic of, Australia, New Zealand, South Africa, United Kingdom, Spain, Ukraine, Hungary, Israel, Bulgaria, Russian Federation, Mexico, Poland, Brazil, Argentina, Malaysia, Puerto Rico, France
Akebia Therapeutics

Completed

Efficacy and Safety Study to Evaluate Vadadustat for the Correction or Maintenance Treatment of Anemia in Participants With Incident Dialysis-dependent Chronic Kidney Disease (DD-CKD)

Anemia | Dialysis-Dependent Chronic Kidney Disease

United States, Italy, Korea, Republic of, Portugal, Russian Federation, Ukraine, Poland, Argentina, Brazil, Germany, Mexico
Göteborg University

Terminated

The Role of Emergency Neutrophils and Glycans in Postoperative and Septic Patients

Sepsis | Septic Shock | SIRS | Sepsis, Severe | Post-Op Complication

Sweden
EyePoint Pharmaceuticals, Inc.

Completed

Study to Assess the Efficacy, Safety and Tolerability of AKB-9778 Ophthalmic Solution as and Adjunct to Latanoprost in Patients With Ocular Hypertension or Open Angle Glaucoma

Primary Open Angle Glaucoma | Ocular Hypertension

United States
Akebia Therapeutics

Completed

A Study in Evaluating Bioequivalence Between Test and Reference Formulations of Vadadustat Tablets in Healthy Adults

Healthy

United States
Akebia Therapeutics

Completed

Drug-Drug Interaction Study of Vadadustat With Digoxin, Adefovir and Furosemide

Drug Interaction Potentiation

Canada
Mitsubishi Tanabe Pharma Corporation

Completed

Efficacy and Safety Study to Evaluate MT-6548 in Hemodialysis Subjects Currently Receiving ESAs With Anemia Associated With Chronic Kidney Disease in Japan

Anemia; Hemodialysis Dependent Chronic Kidney Disease

Japan
Akebia Therapeutics

Completed

16-Week Repeat Oral Dose Study of AKB-6548 for Anemia in Participants With End Stage Renal Disease (ESRD) Requiring Chronic Hemodialysis

Anemia | End Stage Renal Disease

United States
Akebia Therapeutics

Completed

Study in Healthy Adult Subjects to Assess the Effect of Phosphate Binders on the Pharmacokinetics of a Single Dose of Vadadustat

Healthy Volunteers

Canada
Akebia Therapeutics

Completed

Drug-Drug Interaction Study of Vadadustat With Rosuvastatin, Sulfasalazine, Pravastatin, Atorvastatin and Simvastatin

Drug Interaction Potentiation

Canada
Akebia Therapeutics

Completed

Study Evaluating the Efficacy and Safety of Dose Conversion From a Long-acting Erythropoiesis-stimulating Agent (Mircera®) to Three Times Weekly Oral Vadadustat for the Maintenance Treatment of Anemia in Hemodialysis Subjects

Anemia Associated With Chronic Kidney Disease (CKD)

United States
Akebia Therapeutics

Completed

Drug-Drug Interaction Study of Vadadustat With Cyclosporine, Probenecid and Rifampin

Drug Interaction Potentiation

Canada
Akebia Therapeutics

Completed

Study to Evaluate the Effect of Rabeprazole on the Pharmacokinetics of Vadadustat

Pharmacokinetics | Drug Interaction Potentiation

Canada
Mitsubishi Tanabe Pharma Corporation

Completed

Effects of Iron Supplements on the Pharmacokinetics of MT-6548

Healthy

Japan
Aerpio Therapeutics

Completed

The TIME-2 Study: A Phase 2 Study of AKB-9778, a Novel Tie-2 Activator, in Patients With Diabetic Macular Edema (TIME-2)

Diabetic Macular Edema (DME)

United States
EyePoint Pharmaceuticals, Inc.
Medical Technology Enterprise Consortium (MTEC)

Terminated

Evaluation of the Safety and Efficacy of Razuprotafib in Hospitalized Subjects With Coronavirus Disease 2019 (RESCUE)

COVID-19 | Acute Respiratory Distress Syndrome (ARDS)

United States
Bayer

Completed

An Observational Study Called FLAMINgO to Learn More About the Treatment Combination of Finerenone and SGLT2 Inhibitors in People With Long-term Kidney Disease (Chronic Kidney Disease) Together With Type 2 Diabetes by Using Routine Medical Care Data and Past Clinical Study Results (FLAMINGO)

Type 2 Diabetes | Chronic Kidney Disease

United States
Dentsply International

Completed

NUPRO Sensodyne Prophylaxis Paste With NovaMin Sensitivity Relief Study

Tooth Hypersensitivity

United States
Akebia Therapeutics
Otsuka Pharmaceutical Development & Commercialization, Inc.

Completed

Trial Evaluating the Efficacy and Safety of Oral Vadadustat Once Daily (QD) and Three Times Weekly (TIW) for the Maintenance Treatment of Anemia in Hemodialysis Subjects Converting From Erythropoiesis-Stimulating Agents (ESAs)

Anemia

United States, Italy, Spain, Hungary, Czechia, Poland

3

Subscribe